NEW YORK, Nov. 4, 2016 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Lannett Company Inc. ("Lannett" or the "Company") (NYSE: LCI). Such investors are advised to contact Peretz Bronstein or his investor relations analyst Yael Hurwitz at firstname.lastname@example.org or 212-697-6484. The investigation concerns reports that Lannett has unlawfully conspired with other companies to manipulate generic drug prices. Bloomberg News reported that Lannett is being investigated by the Justice Department, along with other companies including Mylan NV, Teva Pharmaceutical Industries Ltd, Allergan Plc, Impax Laboratories Inc., Sun Pharmaceutical Industries Ltd., Mayne Pharma Group Ltd., Endo International Plc and Taro Pharmaceutical Industries Ltd. Bloomberg News said that the "antitrust investigation by the Justice Department, begun about two years ago, now spans more than a dozen companies and about two dozen drugs, according to people familiar with the matter. The grand jury probe is examining whether some executives agreed with one another to raise prices, and the first charges could emerge by the end of the year, they said." Following this news, Lannett stock dropped in value. If you are aware of any facts relating to this investigation, or purchased shares Lannett, you can assist this investigation by visiting the firm's site: http://www.bgandg.com/lci. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484 or via email email@example.com. Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number. Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.